Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (191-200 of 236) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patientsEzra E W Cohen, Kehua Wu, Christine Hartford, et al.
Cancer Cell|May 17, 2024
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacyMarit J van Elsas, Jim Middelburg, Camilla Labrie, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Cell|August 11, 2018
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Blood Advances|August 17, 2022
Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedentsMargo E MacDonald, Rachel K Weathered, Emma C Stewart, et al.
Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Pageof 24

Showing results (191-200 of 236) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patientsEzra E W Cohen, Kehua Wu, Christine Hartford, et al.
Cancer Cell|May 17, 2024
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacyMarit J van Elsas, Jim Middelburg, Camilla Labrie, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Cell|August 11, 2018
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Blood Advances|August 17, 2022
Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedentsMargo E MacDonald, Rachel K Weathered, Emma C Stewart, et al.
Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Pageof 24